PDCD1 and cancer: In line with this, DGKα is upregulated in tumor-infiltrating lymphocytes but also when resistance to PD-1-targeted therapies arises, and its inhibition counteracts such resistance, with the added value of directly hitting DGK-addicted cancer cells [132,133].